Parenteral Drugs (India) Q1, Q2, Q3, Q4, FY 2017-18, FY 2016-17 Standalone / Consolidated Results, Revenues, Net Profit, Tax, EPS, Live Chart …

Parenteral Drugs (India) Company Profile :

Parenteral Drugs (India) Limited is an India Based holding company involved in the business of manufacturing of allopathic pharmaceutical preparations.

Company also manufactures intravenous (IV) Fluids. It offers products in various categories, including IV fluids, oncology, anesthesia and exports. Its IV Fluids include Carbohydrated and Electrolytes, like Dextrose IP 25%, Ringer Lactate IP and Multiple Eletrolytes and Dextrose Injection IP Type I; Diuretics, like Mannitol 10%, 20%; Dialysis and Irrigation Solution, like Peritoneal Dialysis Solution with 1.7% Dextrose; Anti-infective and Anti-fungal, like Ciprofloxacin 200mg, and Others like Tamolgan (Paracetamol 1000mg).

Companys Oncology product mix includes 5 FU-PAR, BLEOPAR, BOTEPAR and BAZIPAR. Its Anesthesia product mix includes Sevoplan (Sevoflurane 100/250ml) and Isoplan (Isoflurane 100/250ml). Its exports products include CIPROFLOXACIN INJECTION USP WITH DEXTROSE and FLUCONAZOLE INJECTION USP.


Parenteral Drugs (India) Ltd ResultsBSE Code : 524689
NSE Symbol :  PDPL
ISIN No. : INE904D01019
Industry : Pharmaceuticals
Face Value : Rs. 10.00


If you are an investor who has shares of Parenteral Drugs (India) or you are an stock market analyst then i am sure you might for Quarterly Results of Parenteral Drugs (India).

In this article you will find Q1, Q2, Q3, Q4 and FY 2017-18 Results of Parenteral Drugs (India). That’s not all, you can compare those results with previous year i.e., FY 2016-17 Results of Parenteral Drugs (India).

3M India Q1 Results 2017-18 :

3M India will announce its Q1 FY 2017-18 Results in August 2017. Will soon update the below mentioned table.

(Values in Cr.) Q1 Standalone Q1 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

3M India will announce its Q2 FY 2017-18 Results in the month of October 2017.

(Values in Cr.) Q2 Standalone Q2 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

3M India will announce its Q3 FY 2017-18 Results in the month of January 2018.

(Values in Cr.) Q3 Standalone Q3 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

3M India will announce its Q4 FY 2017-18 Results in the month of April 2018.

(Values in Cr.) Q4 Standalone Q4 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

3M India will announce its FY 2017-18 Results in the month of April 2018.

(Values in Cr.) FY 2017-18 Standalone FY 2017-18 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

Note : We will update the results table above as and when results are announced. Visit again.

3M India Previous Year’s Results (FY 2016-17) :

(Values in Cr.) FY 2016-17 Standalone FY 2016-17 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax
Net Profit
Equity
EPS

Note : If you like this information about Parenteral Drugs (India) Quarterly Results, then please share it with all your friends, relatives and other investors on Facebook, Twitter, WhatsApp, Email, etc.